Emory University

Cocrystal Pharma, Inc.

Rfs Pharma LLC

University of Pittsburgh

Hongwang Zhang

Raymond F Schinazi

Steven J Coats

Longhu Zhou

Richard Anthony Whitaker

Junxing Shi

Franck Amblard

Tamara Rosario McBrayer

Jong Hyun Cho

John W Mellors

Nicolas Paul Sluis-Cremer

Brian David Herman

The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.

Potent and selective inhibitors of hepatitis C virus

The present invention is directed to compounds, compositions and methods for treating or preventing cancer and viral infections, in particular, HIV, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV in human patients or other animal hosts. The compounds are certain 6-substituted purine monophosphates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1, HIV-2, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV.

Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections

The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HIV, and HBV, in human patients or other animal hosts. The compounds are 3'-azido-2&#x2032;,3&#x2032;-dideoxy purine monophosphates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1 and HBV.

3'-azido purine nucleotide prodrugs for treatment of viral infections

Growing community of inventors

Tucker, GA, United States of America

Hongwang Zhang